Thank you, operator.
begin, call. to prevented our him I will this that which CEO, able being Dave I to present Before Rosa, I wanted from afternoon, surgery the had handling minor so mention be
first to fiscal our the product quarter on progress commercialization continued development. relating significant we objectives XXXX, make to and of During
would First, an utilizing electrical achievement clearance ablation tissue receiving the FDA like the recent first of activity our same system remind OneRF the milestone I both audience nervous recording of use System, for FDA-cleared our to for and of device. Ablation intended with
neurosurgical As Ablation XXX(k) noted, the And the in for June received we procedures. OneRF radio frequency of of the creation tissue XXX(k) FDA submitted functional XXXX to nervous previously application a in the for clearance FDA for from we December System. a XXXX in lesions
in the quarter launch and excited be commercial of market States to novel the United very XXXX. are technology preparing to calendar We second a to first are the in limited initiate this
expect our brain near licensing potential ablation regarding commercialization decision in regarding for the of technology in strategy. to remain with a discussions the will partners reach We procedures, and we future the strategic
the company, to commercializing launch we we device a and directly. option We are the for believe it also plan if in to working represents technology on the best parallel remain directly open the
that further to provide We there an team address, product the for opportunities Biomet. sEEG and provide I our are our to we OneRF will expanded the would Evo exploring updates treat future. applications that additional OneRF to electrode we believe the other in system Zimmer partner, In able update addition, commercialization the for system market is our of launch pain. be line regarding now with like may
to sEEG the launch continued and we the expands. fiscal demand performance, expect our Zimmer will device remains Zimmer Customer on and and regarding Evo launch usage customer sales open for line. training product the new the XXXX, we a picking full also believe seeing are positive strategically Evo sales to revenue recent centers in impact as see for in We electrode increase of an OneRF first during in positive up sEEG system We January have quarter. completed force months. feedback
delivery Moving on to drug our program.
potential the electrode as discussed the deliver to sEEG record therapies have for our therapy's the brain technology well We to impact. gene drugs or as
and recording system. deliver During quarter, demonstrating the benchtop and the provide feasibility to study we ability the using drug sEEG testing an a capabilities past animal completed therapy delivery
in discussions partners. our studies contract regarding other discussions with in a currently company interest in potential using are with upcoming We device biotech their had have and clinical
its in procedures. this biopharma may prospects or the excited in of development the their delivery clinically assist neurosurgical technology value and also, are how therapy We and with industry gene it drug current
a stimulation spinal technology in to in negotiations, efforts reach chronic current X-millimeter our cortical concept the If a XXXX. similar paddle film model. in Board, or in percutaneous our continued to first calendar Advisory in the of treat has approach utilizing placement our are revenue Paddle add our to cord contract quarter able we Physician as back with year cadaver an electrodes. placed agreement are a program pain members to electrodes Development potential electrode, successfully later
of model. of technology. stimulation the In lead competitive preclinical advantages first electrophysiology experiment of addition, opportunity and a with a in our priority, the acute cord market potential NeuroOne's given study and Spinal size the pain the completed we sheep a management remain
portion of in the and now first eligible quarter the would collaboration Agreement like first period. revenue Development to of represents Collaboration payments revenue collaboration of I recognition fiscal the $XXX,XXX million was compared revenue had quarter first the and Product of no for XXXX. XXXX The XXXX of the revenue revenue of financial fiscal quarter fee provide to in quarter fiscal of product was results. exclusivity a fiscal milestone XXXX in our Zimmer $XXX,XXX review first fiscal the revenue compared the company XXXX. year during were of quarter in from to in 'XX $X.XXX derived that the first
was of the quarter first net of of expenses loss operating were in fiscal $X.X fiscal expense fiscal XXXX. million was of $X.X million XXXX. in to in quarter for the $X.X fiscal to a 'XX, XXXX. million $X.X net fiscal $X.X to quarter first first expense the first loss fiscal with $X.X million Total $X.X million fiscal million compared million in period the quarter compared quarter The the R&D of the SG&A of fiscal XXXX million 'XX the compared of compared same the XXXX $X.X was first in quarter in XXXX. of of in first first quarter
stock average and the share offering In price December company of $X.XX of under the at sold $X.X per million. ATM net common proceeds an received of XXXX,
The million $X.X million XXXX compared XX, $X.X short-term our investments working As of $X.X previous of XXXX, XX, fiscal capital company of as of working $X.X XX, capital had company XXXX, XXXX. of as of December the September equivalents year-end. had XX, to December million as September to million cash cash, compared and of
under average net $X.XX proceeds additional ATM $X.XX share as had company XX, the of company of the stock and January outstanding at the to Subsequent million. end received common of in an of The first XXXX. December per XXXX, the debt no offering quarter of sold price
Operator, at think for I open this up questions. we can time,
